Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.41 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | SLC18A3 | Q16572 | 3/20 | 0.33 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.30 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.30 |
| ▸ | PTGIR | P43119 | 1/20 | 0.30 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13077531 | 0.88 | ADRB2 (0.43) | ADRB2ADRB1ADRA1ARECQLLMNA | |
| SCHEMBL13040085 | 0.87 | ADRB2 (0.43) | ADRB2ADRB1ADRA1ARECQLLMNA | |
| SCHEMBL13040084 | 0.85 | ADRB2 (0.56) | ADRB2ADRB1ADRA1ARECQLLMNA | |
| SCHEMBL13040102 | 0.81 | CYP2D6 (0.40) | ADRA1A | |
| SCHEMBL13077494 | 0.76 | ADRB2 (0.44) | ADRB2ADRB1ADRA1ARECQLLMNA | |
| SCHEMBL13040080 | 0.75 | ADRB2 (0.56) | ADRB2ADRB1ADRA1ARECQLLMNA | |
| SCHEMBL13077540 | 0.73 | ADRB2 (0.58) | ADRB2ADRB1ADRA1ARECQLLMNA | |
| SCHEMBL14571126 | 0.73 | ADRB2 (0.51) | ADRB2ADRB1ADRA1ARECQLLMNA | |
| SCHEMBL13040076 | 0.70 | ADRB2 (0.55) | ADRB2ADRB1ADRA1ARECQLLMNA | |
| SCHEMBL13040039 | 0.69 | NR2E1 (0.37) | ADRB2ADRB1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7825263-B2 | Nitrooxyderivatives of carvedilol and other beta blockers as antihypertensive | NICOX S.A. (FR) | 2010-11-02 | — | — | US | disclosed |
| US-20070072854-A1 | Nitrooxyderivatives of carvedilol and other beta blockers as antihypertensive | NICOX S.A. (FR) | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072854-A1 | Nitrooxyderivatives of carvedilol and other beta blockers as antihypertensive | ADRB2, ADRB1, ADRA2B | ADRB2 1/4885ADRB1 2/4885ADRA1A 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.